BETRF (BetterLife Pharma) Total Current Assets : $0.33 Mil (As of Jul. 2024)

View and export this data going back to 2010. Start your Free Trial

What is BetterLife Pharma Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. BetterLife Pharma's total current assets for the quarter that ended in Jul. 2024 was $0.33 Mil.

BetterLife Pharma Total Current Assets Historical Data

The historical data trend for BetterLife Pharma's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BetterLife Pharma Total Current Assets Chart

BetterLife Pharma Annual Data

Trend

Jan15

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Total Current Assets

Get a 7-Day Free Trial

2.66

1.05

0.91

0.06

0.24

BetterLife Pharma Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Total Current Assets	Get a 7-Day Free Trial															0.30	0.37	0.24	0.58	0.33

BetterLife Pharma Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

BetterLife Pharma's Total Current Assets for the fiscal year that ended in Jan. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.028	+	0.03	+	0	+	0.184
	=	0.24

BetterLife Pharma's Total Current Assets for the quarter that ended in Jul. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	0.092	+	0.018	+	0	+	0.218
	=	0.33

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

BetterLife Pharma (OTCPK:BETRF) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

BetterLife Pharma's Liquidation Value for the quarter that ended in Jul. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.092	-	5.849	+	0.75 * 0.018	+	0.5 * 0
=	-5.74

BetterLife Pharma Total Current Assets Related Terms

Thank you for viewing the detailed overview of BetterLife Pharma's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

BetterLife Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BetterLife Pharma Inc (OTCPK:BETRF) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

NPAU:Germany BETR:Canada

Address

1275 West 6th Avenue, Suite 300, Vancouver, BC, CAN, V6H 1A6

Website

https://www.abetterlifepharma.com

BetterLife Pharma Inc a biotechnology company, engages in the development and commercialization of psychedelic products for the treatment of mental disorders in Canada, the United States, Australia, and the European Union. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections, such as coronavirus disease and human papillomavirus, and/or to directly inhibit tumors to treat various types of cancer.

Executives

Barbara-jean Anne Bormann-kennedy	director, officer: President	1188 BROADWAY, SUITE 306, SOMERVILLE MA 02144
Moira Ong	officer: Chief Financial Officer	2392 LAWSON AVENUE, WEST VANCOUVER A1 V7V 2E6
Hassan Salari	director, 10 percent owner	1517 WEST 58TH AVENUE, VANCOUVER A1 V6P 1W6
Ahmad Doroudian	director, officer: Chairman	1275 WEST 6TH AVENUE, VANCOUVER A1 V6H 1A6